Patients Are Asking Chatbots About Their Prescriptions

The drugmakers competing for a $5.6 trillion global medicine market are now being researched inside the chatbox. New 5W research ranks the 25 pharmaceutical companies by how often the AI engines name them.

Revenue rank does not predict citation rank.

Pharma is a $5.6 trillion global industry, and by conventional measures its leaders are Merck — maker of Keytruda, the best-selling drug in the world — alongside Pfizer, Johnson & Johnson, and AbbVie. Those are the companies at the top of the revenue tables.

They are not the companies at the top of the AI answer. The 5W AI Visibility Index finds that Eli Lilly and Novo Nordisk lead the consumer-citation surface — because their drugs are the ones patients actually research. Ozempic, Wegovy, Mounjaro, and Zepbound generated roughly $70 billion in combined 2025 sales and, more importantly, became household names. When a consumer asks ChatGPT or Google's AI Overviews about weight loss, diabetes, or "Ozempic vs Wegovy," the company names that surface are Lilly and Novo.

Keytruda outsells every drug on earth, but oncology medicines are prescribed, not shopped — patients do not type Keytruda into a chatbot the way they type Ozempic. That is the decoupling: consumer AI citation share is driven by the drugs people self-research, not the drugs that earn the most. In a category where patients increasingly research their prescriptions before they research their doctor, the company AI names is the company shaping the conversation.

"Merck makes the best-selling drug in the world. Most patients have never typed its name into a chatbot. Eli Lilly and Novo Nordisk built something more valuable than the top seller — they built the drugs people actually ask AI about. Ozempic and Mounjaro turned two companies into household names inside the answer engines, and the pharma giants ranked by revenue are not the ones ranked by citation. In a category where patients now research their prescriptions before they research their doctor, the company AI names is the company that shapes the conversation."

How we measured it.

5W analyzed more than 60 common patient and consumer prompts across six primary sub-categories of the pharmaceutical market, running each prompt five times per engine in clean sessions. We identified which companies AI models consistently surface, which sources feed those citations, and where the biggest gaps sit between revenue and AI visibility.

Metabolic & GLP-1

Eli Lilly, Novo Nordisk, and the diabetes/obesity drug makers.

Oncology

Merck, AstraZeneca, Bristol Myers Squibb, Roche, Pfizer oncology.

Immunology & inflammation

AbbVie, Sanofi, Amgen, and the autoimmune-drug makers.

Vaccines & antivirals

Pfizer, Moderna, GSK, Gilead Sciences.

Cardiovascular & specialty

Novartis, Bristol Myers Squibb, Bayer, specialty makers.

Generics & biosimilars

Teva, Viatris, Organon, and biosimilar producers.

Query types tracked. Real-world prompts including "which company makes Ozempic," "Ozempic vs Wegovy vs Mounjaro," "largest pharmaceutical companies," "who makes the COVID vaccine," "best company for diabetes drugs," "what company makes Humira," and 50+ variations covering company-identification, comparison, and category-leadership intent. Prompts were framed at the company and category level, not as treatment-selection queries.

Citation sources tracked. Business and health editorial (Reuters, Bloomberg, Fierce Pharma, STAT, Pharm Exec), reference sources (company filings, Wikipedia, Drugs.com), news coverage, and brand-owned corporate content.

The Top 25 pharmaceutical companies, ranked by AI citation share.

The companies winning the AI answer.

▲ Eli Lilly — the GLP-1 Citation Engine

Mounjaro and Zepbound did more than drive revenue — they made Eli Lilly a household name inside the answer engines. When consumers research weight loss or diabetes, Lilly is the company AI surfaces, and that consumer-citation lead has no equal in the category.

▲ Novo Nordisk — Ozempic as a Brand Halo

Ozempic became one of the most-searched drug names in the world, and Wegovy extended it into obesity. That recognition pulls Novo Nordisk's corporate name into a huge share of consumer health queries — visibility a traditional campaign could never buy.

▲ Pfizer — the Pandemic Recognition Dividend

The COVID-19 vaccine made Pfizer one of the most recognized company names on earth. That recognition still compounds: Pfizer ranks third in citations, well above where its current revenue mix alone would place it.

▲ AbbVie — Direct-to-Consumer as Citation Fuel

AbbVie's heavy direct-to-consumer advertising for Humira, Skyrizi, and Rinvoq put its drug names into wide public circulation — and that circulation feeds editorial coverage and citations the engines retrieve.

The companies AI is leaving behind.

▼ Oncology-Led Giants in Consumer Queries

Merck makes the best-selling drug in the world, yet ranks fifth in citations. Oncology medicines are prescribed by specialists, not researched by patients shopping — so the consumer-citation surface badly trails oncology revenue.

▼ Diversified Conglomerates

Bayer and other conglomerates split their identity across pharma, consumer health, and unrelated businesses. That diffuse structure dilutes pharmaceutical citation share — the engines cannot attribute a clear category position.

▼ Privately Held Drugmakers

Private companies generate less of the filings, investor coverage, and news flow that feed AI citations. Capable private drugmakers underindex relative to their actual scale.

▼ Generics Cited Only on Price

Teva and Viatris are major manufacturers, but they surface mainly in affordability and access queries. AI answers about specific conditions route to branded innovators, leaving generics in a narrow citation lane.

General tips for pharmaceutical communications teams.

1. Audit corporate AI citation share quarterly. Pipeline news, trial readouts, and pricing coverage move the surface fast.
2. Connect the drug brand to the company name. A blockbuster only builds corporate citation share if the AI-retrievable record links drug and maker clearly.
3. Build authoritative corporate and disease-state content. Accurate, well-sourced corporate content feeds the engines a reliable record to cite.
4. Earn the business and health editorial record. Reuters, Bloomberg, STAT, and Fierce Pharma feed pharma citations disproportionately.
5. Keep reference sources accurate. Company filings, Drugs.com, and Wikipedia are heavily retrieved — errors there propagate into AI answers.
6. Treat trial readouts and approvals as citation events. Major clinical milestones reshape company citations; publish substantive content around them.
7. Engage pricing and access narratives directly. AI answers increasingly surface pricing context — address it in corporate content rather than ceding the framing.
8. Consolidate a clear category identity. A defined therapeutic position out-cites a diffuse conglomerate profile.
9. Maintain strict promotional and regulatory compliance. AI-visibility content must stay within pharmaceutical advertising and regulatory rules — never imply treatment guidance.
10. Re-audit after every major launch, readout, or patent event. Each materially reshapes the citation surface.

The prescription conversation now starts before the appointment.

For decades, pharmaceutical brand awareness was shaped by detailing to physicians and direct-to-consumer advertising. Today a growing share of patients arrive at the doctor's office having already asked ChatGPT, Claude, or Google's AI Overviews about their condition and their options. The citation surface has become upstream of the prescription itself.

The Index shows what that surface rewards: the drugs patients self-research, the company names a blockbuster drags into public consciousness, a clear category identity, and a deep, accurate editorial and reference record. It does not simply track revenue — Merck's best-in-world drug does not make Merck the best-cited company.

AI citation share is the scoreboard. In pharma, the company AI names is the company shaping how patients understand their options — and that visibility is built in the public record, not the revenue table.

The Pharma / Rx AI Visibility Index 2026.

CVS wins the AI answer for pharmacy. Hims wins the prescription. New 5W research ranks 25 pharma and Rx brands by citation share across ChatGPT, Claude, Perplexity, and Gemini. /ai-visibility-index/pharma-rx-ai-visibility-index-2026

New 5W research: CVS dominates AI citation share for pharmacy. Hims wins the prescription question. The 5W AI Visibility Index ranked 25 pharma and Rx brands across ChatGPT, Claude, Perplexity, Gemini, and Google AI Overviews — and the DTC brands are taking the AI answer from legacy chains. /ai-visibility-index/pharma-rx-ai-visibility-index-2026